The pharmacy day | A question to investigate
A promising pilot is the beginning of the investment case
A service that works in a well-supported branch does not automatically work across a large pharmacy network. The first site may have unusually stable staffing, a highly engaged manager or access to a room that is scarce elsewhere. At scale, those differences become the programme. The commercial challenge is to discover the conditions that make an intervention worth repeating before a national commitment turns a small uncertainty into a large operating cost.
In the conversation.
NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.
Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.
Define the decision at each stage
Separate discovery, feasibility, comparative evaluation and expansion. Discovery asks whether the problem is substantial and shared. Feasibility asks whether the proposed change can fit ordinary operations. Evaluation examines whether it produces a worthwhile difference. Expansion asks whether the necessary conditions are available across the intended estate. These are different investment decisions, and the evidence required to pass each should be written before the programme starts collecting attractive examples.
Build a representative test rather than a showcase
Select branches to expose variation in setting, workload, staffing and patient access. Include a credible reason to expect the intervention might struggle. Record which sites declined or could not participate and why. A pilot supported by exceptional central resources can still teach something valuable, provided those resources are counted. It becomes misleading when the support disappears from the business case and the selected branches are presented as typical of the estate.
Preserve local professional accountability
National consistency should help local teams understand responsibilities, not erase their judgement. GPhC standards remain relevant to the operation of individual pharmacies (General Pharmaceutical Council, n.d.). For prescribing-based services, NHS England's commissioning guidance addresses pathway design, governance and professional support (NHS England, n.d.). The evaluation therefore needs a route for staff to raise implementation concerns and a clear account of which decisions remain local, which are central and which require commissioner or clinical agreement.
An investment gate with four visible answers
At each review, ask whether the problem is evidenced, the operating change is feasible, the observed difference is worthwhile and the conditions for repetition are available. Give each answer its own evidence and owner. A positive result on three does not cancel a failure on the fourth. This creates an expansion map: suitable now, suitable after a defined dependency, unsuitable under current conditions and not yet understood, instead of one estate-wide average.
A promising branch is not the whole network.
An investment case gets stronger when it explains the conditions for repetition. Make the next commitment depend on evidence.
A large network has an encouraging local test but does not know whether the required conditions exist across the estate. The decision is whether to expand now, narrow the intended cohort or investigate a missing dependency.
Supports an investable boundary: suitable now, suitable after a defined dependency, unsuitable under present conditions or still unknown.
What would we need to understand?
- The specific operating change and decision owner
- Baseline service mix and professional cover
- Central and local implementation effort
- Site differences, non-participation and exceptions
Constructed decision example | No customer results are shown.
Test the full delivery package
A proposed PHARMORIS programme could compare an agreed workflow in a small, deliberately varied branch cohort. Inputs would include baseline activity, staff and training requirements, exception handling, central support time and authorised aggregate service records. The comparator should describe ordinary practice accurately. Outcomes might include completion, implementation effort, service continuity and cost per completed eligible episode, with professional quality measures agreed separately by those responsible for the service.
Distinguish scale efficiencies from shifted costs
A central process can reduce duplication in branches while increasing the burden on support teams. Show both. Include recurrent software and training costs, implementation disruption, regional management and the cost of branches that cannot adopt. Model several adoption levels instead of assuming every location behaves like the first. Claimed capacity should have an intended use; redeployment, reduced overtime and cash savings are different outcomes with different requirements to become real.
Why the pharmacy role is changing.
David Webb's introduction to Pharmacy First, recorded for Community Pharmacy England's December 2023 webinar. The original strategic context, with current service documents beside it.
Community Pharmacy England | Uploaded 18 December 2023
David Webb, Chief Pharmaceutical Officer, NHS England talks about the Pharmacy First service
Community Pharmacy England (2023) | 8 min 3 sec
Loads the YouTube player when you choose to watch.
Medicines context photograph | Source
Community Pharmacy England (2023) | Original film | Historical educational context
Current service guidance | Pharmacy First service specification
Published by Community Pharmacy England. Included as an external reference; no endorsement of NEUVIOR or PHARMORIS is implied.
Give the programme an honest exit
Agree stop criteria for safety concerns, unacceptable workload, incomplete data and weak adoption. A no-go decision can protect investment even when the concept remains appealing. A partial result may support a restricted rollout to branches with identifiable conditions, rather than abandonment or universal deployment. The decision record should explain the boundary: where the idea appears useful, where uncertainty remains and what further evidence would justify moving that boundary.
Make the next conversation specific
Bring the operating change, the part of the estate it is intended for and the evidence currently supporting expansion. We would aim to identify the next decision that needs confidence and design a bounded way to obtain it. PHARMORIS is a development programme, so any evaluation scope, available capability and delivery commitment would need to be agreed explicitly. The ambition is a clearer path from promising idea to responsible commercial scale.
Sources and scope
GPhC | Registered pharmacy standards | NHS England | Commissioning pharmacy prescribing-based services
General Pharmaceutical Council (n.d.) Registered pharmacy standards. Available at: https://inspections.pharmacyregulation.org/standards (Accessed: 14 October 2026).
NHS England (n.d.) Commissioning pharmacy prescribing-based services. Available at: https://www.england.nhs.uk/long-read/commissioning-guidance-for-community-pharmacy-prescribing-based-services/ (Accessed: 14 October 2026).
Another useful angle.
- Independent pharmacy | Make the next service earn its place
A practical decision framework for independent owners comparing service demand, capacity, costs and cash before expanding.
- Supermarket pharmacies | Turn access into a coherent service
Explore the operational questions between supermarket footfall, pharmacy enquiries, clinical capacity and completed services.
- Pharmacy First | Find the friction in the referral journey
A focused operational evaluation of Pharmacy First referrals, capacity, completion and onward handovers.